Liposome Drug Delivery in Cancer Chemotherapy: Review and Multifactorial Analysis

We reviewed the use of liposomes for cancer therapy using computational biostatistics. We used virtual libraries, such as PubMed, LILACS, National Health Institute (NHI) and the Food Drug Administration (FDA) to conduct the review. Cluster analysis and correlation were developed using the Tanimoto coefficient (TC) of 0.7 using the modeling tool ChemMine Tools from databases (PubChem, DailyMed, DrugBank, Drug @ FDA). The results pointed fifteen molecules in the pharmaceutical form of liposome for the oncological clinic. Of these, 13 are classified by size into small-molecules and were analyzed by computational statistical modeling. Of these, only 4 were approved for use by the FDA, and 9 are in phases of research by the pharmaceutical industry as liposomal formulations. Essential differences in physical-chemical properties and molecules structure were observed, indicating original proposal in the development of liposomal as an anticancer drugs.